Product
IMM-1-104 Monotherapy
1 clinical trial
4 indications
Indication
Advanced Solid TumorIndication
Pancreatic adenocarcinomaIndication
Malignant MelanomaIndication
NSCLCClinical trial
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-01